Selective serotonin reuptake inhibitors affect structure, function and metabolism of skeletal muscle: A systematic review

Visco, Diego Bulcão; Manhães-de-Castro, Raul; Chaves, Wenicios Ferreira; Lacerda, Diego Cabral; Pereira, Sabrina da Conceição; Ferraz-Pereira, Kelli Nogueira; Toscano, Ana Elisa

doi:10.1016/j.phrs.2018.09.004

Cited by 8 publications

(6 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serotonin has also been implicated in insulin secretion and glucose uptake (Hajduch et al, 1999), and may interact with myostatin to regulate glucose metabolism in skeletal muscle (Chandran et al, 2012). Use of SSRIs is known to affect muscle function and energy metabolism in skeletal muscle tissue (Visco et al, 2018). Hence, further investigation of the mechanisms by which serotonin modulation impacts muscle health may guide research towards an effective pharmacologic treatment, perhaps by means other than our candidate drugs.…”

Section: Discussionmentioning

confidence: 99%

Effect of serotonin modulation on dystrophin-deficient zebrafish

et al. 2020

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease caused by mutation of the dystrophin gene. Pharmacological therapies that function independently of dystrophin and complement strategies aimed at dystrophin restoration could significantly improve patient outcomes. Previous observations have suggested that serotonin pathway modulation ameliorates dystrophic pathology, and re-application of serotonin modulators already used clinically would potentially hasten availability to DMD patients. In our study, we used dystrophin-deficient sapje and sapje-like zebrafish models of DMD for rapid and easy screening of several classes of serotonin pathway modulators as potential therapeutics. None of the candidate drugs tested significantly decreased the percentage of zebrafish exhibiting the dystrophic muscle phenotype in the short-term birefringence assay or lengthened the lifespan in the long-term survival assay. Although we did not identify an effective drug, we believe our data is of value to the DMD research community for future studies, and there is evidence that suggests serotonin modulation may still be a viable treatment strategy with further investigation. Given the widespread clinical use of selective serotonin reuptake inhibitors, tricyclic antidepressants and reversible inhibitors of monoamine oxidase, their reapplication to DMD is an attractive strategy in the field's pursuit to identify pharmacological therapies to complement dystrophin restoration strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of serotonin modulation on dystrophin-deficient zebrafish

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although SSRIs mono‐class therapy had an association with a lower risk of DM, the risk of multi‐drug combinations containing SSRIs was relatively high and largely depended on what the other drugs in that combination were 164 . In skeletal muscle tissue, SSRIs could exert influence on the metabolism of energy, structure properties and electrical muscle activity 165 . Therefore, reducing the administration of SSRIs could moderate the risk of first falls and fractures among individuals who have diabetes 166 .…”

Section: Treatmentmentioning

confidence: 99%

“… 164 In skeletal muscle tissue, SSRIs could exert influence on the metabolism of energy, structure properties and electrical muscle activity. 165 Therefore, reducing the administration of SSRIs could moderate the risk of first falls and fractures among individuals who have diabetes. 166 Multivariate analysis suggested that SSRIs were the risk factor for CAN (cardiovascular autonomic neuropathy) in T1DM.…”

Section: Treatmentmentioning

confidence: 99%

Neurological and metabolic related pathophysiologies and treatment of comorbid diabetes with depression

Li,

Yang,

Zhou

et al. 2023

CNS Neurosci Ther

View full text Add to dashboard Cite

BackgroundThe comorbidity between diabetes mellitus and depression was revealed, and diabetes mellitus increased the prevalence of depressive disorder, which ranked 13th in the leading causes of disability‐adjusted life‐years. Insulin resistance, which is common in diabetes mellitus, has increased the risk of depressive symptoms in both humans and animals. However, the mechanisms behind the comorbidity are multi‐factorial and complicated. There is still no causal chain to explain the comorbidity exactly. Moreover, Selective serotonin reuptake inhibitors, insulin and metformin, which are recommended for treating diabetes mellitus‐induced depression, were found to be a risk factor in some complications of diabetes.AimsGiven these problems, many researchers made remarkable efforts to analyze diabetes complicating depression from different aspects, including insulin resistance, stress and Hypothalamic–Pituitary–Adrenal axis, neurological system, oxidative stress, and inflammation. Drug therapy, such as Hydrogen Sulfide, Cannabidiol, Ascorbic Acid and Hesperidin, are conducive to alleviating diabetes mellitus and depression. Here, we reviewed the exact pathophysiology underlying the comorbidity between depressive disorder and diabetes mellitus and drug therapy.MethodsThe review refers to the available literature in PubMed and Web of Science, searching critical terms related to diabetes mellitus, depression and drug therapy.ResultsIn this review, we found that brain structure and function, neurogenesis, brain‐derived neurotrophic factor and glucose and lipid metabolism were involved in the pathophysiology of the comorbidity. Obesity might lead to diabetes mellitus and depression through reduced adiponectin and increased leptin and resistin. In addition, drug therapy displayed in this review could expand the region of potential therapy.ConclusionsThe review summarizes the mechanisms underlying the comorbidity. It also overviews drug therapy with anti‐diabetic and anti‐depressant effects.

show abstract

“…The authors have shown a possible relationship between the lifespan and severity of the disease and alterations in glucose metabolism and lipid profiles in patients with idiopathic pulmonary arterial hypertension (IPAH). Selective serotonin reuptake inhibitors (SSRI) are worldwide prescribed anti-depressant drugs and they increase the risk of cardiovascular diseases [2,3]. A recent report has shown that use of SSRI definitely induces pulmonary artery hypertension [4].…”

Section: Prognostic Role Of Traditional Cardiovascular Risk Factors Imentioning

confidence: 99%

Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension

Kalemci¹,

Sarihan²,

Zeybek³

et al. 2020

aoms

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors affect structure, function and metabolism of skeletal muscle: A systematic review

Cited by 8 publications

References 73 publications

Effect of serotonin modulation on dystrophin-deficient zebrafish

Effect of serotonin modulation on dystrophin-deficient zebrafish

Neurological and metabolic related pathophysiologies and treatment of comorbid diabetes with depression

Prognostic role of traditional cardiovascular risk factors in patients with idiopathic pulmonary arterial hypertension

Contact Info

Product

Resources

About